FindTrial
Sign In

Voglibose

DRUG11 trials

Sponsors

National Cerebral and Cardiovascular Center, Japan, Boehringer Ingelheim, JW Pharmaceutical, Merck Sharp & Dohme LLC, Takeda

Conditions

Diabetes Mellitus, Non-Insulin-DependentDiabetes Mellitus, Type 2Impaired Glucose ToleranceInsulin Sensitivity/ResistanceMyocardial InfarctionType 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
CompletedNCT01263470
TakedaDiabetes Mellitus, Type 2
Start: 2007-01-31End: 2007-12-31Updated: 2012-02-03
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
CompletedNCT01263483
TakedaType 2 Diabetes Mellitus
Start: 2007-01-31End: 2008-04-30Updated: 2012-02-03
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
CompletedNCT01263496
TakedaType 2 Diabetes Mellitus
Start: 2007-05-31End: 2008-09-30Updated: 2012-02-03

Phase 3

Japanese P III vs Voglibose and Placebo
CompletedNCT00654381
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2008-04-30Updated: 2014-01-27
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
CompletedNCT00837577
Merck Sharp & Dohme LLCDiabetes Mellitus, Non-Insulin-Dependent
Start: 2009-02-05End: 2010-08-11Updated: 2017-05-15

Phase 4

Glufast On Insulin Glargine Trial in Type 2 DM
CompletedNCT00663884
JW PharmaceuticalDiabetes Mellitus, Type 2
Start: 2008-02-29End: 2009-09-30Updated: 2012-03-30
Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes
CompletedNCT01309698
Novartis PharmaceuticalsType 2 Diabetes
Start: 2011-02-28Updated: 2020-12-19
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
CompletedNCT02049814
TakedaType 2 Diabetes Mellitus
Start: 2014-05-09End: 2016-06-28Updated: 2019-03-13
Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
NCT02097342
Post Graduate Institute of Medical Education and Research, ChandigarhInsulin Sensitivity/Resistance, Type 2 Diabetes Mellitus
Start: 2013-12-31End: 2015-01-31Target: 30Updated: 2014-04-08

Unknown Phase

Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT
TerminatedNCT00212017
National Cerebral and Cardiovascular Center, JapanImpaired Glucose Tolerance, Myocardial Infarction
Start: 2005-04-30End: 2017-08-31Updated: 2018-08-22
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance Long-term Use in Patients With Impaired Glucose Tolerance
CompletedNCT01993927
TakedaImpaired Glucose Tolerance
Start: 2009-11-18End: 2013-08-31Updated: 2018-12-04

Related Papers

Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
BMC Pharmacology and Toxicology2018-07-039 citations
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
2017-08-0115 citations
How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014
Figshare2014-01-01
Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
Journal of Diabetes Investigation2013-07-2122 citations
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
2011-11-0142 citations